QR-421a showed early and encouraging evidence of activity, with 25% of patients showing a benefit across multiple concordant outcome measures and was well tolerated with no serious adverse eventsQR-421a is the second ophthalmology program where clinical activity was predicted by tra
ProQR Therapeutics today announced positive results from a planned analysis of its Phase 1/2 Stellar trial of QR-421a in adults with Usher syndrome and non-syndromic retinitis pigmentosa (nsRP) due to USH2A exon 13 mutations.
… at the upcoming Seventh Annual Retinal Cell and Gene Therapy Innovation Summit and the ARVO 2022 Annual Meeting … to focus on accelerating the development of Axiomer ® RNA base-editing technology platform across multiple … to changing lives through the creation of transformative RNA therapies, today provided an update on its sepofarsen …
… ProQR is accelerating the development of its Axiomer ® RNA base-editing technology platform across multiple … to changing lives through the creation of transformative RNA therapies, today reported its financial and operating … s epofarsen Sepofarsen (QR-110) is an investigational RNAtherapy designed to restore vision in Leber congenital …
… ProQR is accelerating the development of its Axiomer ® RNA base-editing technology platform across multiple … to changing lives through the creation of transformative RNA therapies, today reported its financial and operating … were presented at the Seventh Annual Retinal Cell and Gene Therapy Innovation Summit, April 29, 2022, and the …
… to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today … trial and is a first-in-class investigational RNAtherapy designed to address the underlying cause of Leber …
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 02, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 23, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for
… to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today … QR-421a QR-421a is a first-in-class investigational RNAtherapy designed to address the underlying cause of vision …